Definitive Healthcare Corp. (DH)
| Market Cap | 144.95M |
| Revenue (ttm) | 241.52M |
| Net Income (ttm) | -138.93M |
| Shares Out | 142.81M |
| EPS (ttm) | -1.30 |
| PE Ratio | n/a |
| Forward PE | 6.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 133,054 |
| Open | 1.010 |
| Previous Close | 1.010 |
| Day's Range | 0.990 - 1.020 |
| 52-Week Range | 0.920 - 4.700 |
| Beta | 1.60 |
| Analysts | Hold |
| Price Target | 3.08 (+203.45%) |
| Earnings Date | May 7, 2026 |
About DH
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company’s platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician... [Read more]
Financial Performance
In 2025, Definitive Healthcare's revenue was $241.52 million, a decrease of -4.24% compared to the previous year's $252.20 million. Losses were -$138.93 million, -66.37% less than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for DH stock is "Hold." The 12-month stock price target is $3.08, which is an increase of 203.45% from the latest price.
News
Definitive Healthcare Announces Timing of Its First Quarter 2026 Financial Results Conference Call and Webcast
FRAMINGHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced th...
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Definitive Healthcare Earnings Call Transcript: Q4 2025
Q4 revenue and profitability exceeded guidance despite a 1% year-over-year revenue decline, with strong cash flow and margin expansion. Retention rates improved, claims data volumes were restored, and diversified/provider segments returned to growth, while 2026 guidance reflects continued top-line pressure but improved operational execution.
Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2025
FRAMINGHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, to...
Definitive Healthcare Announces Timing of Its Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast
FRAMINGHAM, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced tha...
Definitive Healthcare Transcript: 28th Annual Needham Growth Conference Virtual
A four-pillar strategy—data differentiation, integration, customer success, and innovation—has driven operational improvements, higher retention, and new growth opportunities. Recent investments in data quality, platform integration, and digital partnerships are positioning the business for renewed growth and margin stability in 2026.
Definitive Healthcare to Present at the 28th Annual Needham Growth Conference
FRAMINGHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that its Chief Financial Officer, C...
Definitive Healthcare Earnings Call Transcript: Q3 2025
Q3 2025 results were at or above guidance, with $60M revenue (down 4% YoY) and strong cash flow. Enterprise customer count grew, renewal rates improved, and digital partnerships expanded, but life sciences upsell remains pressured. Cautious outlook continues amid macro and renewal headwinds.
Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2025
FRAMINGHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, toda...
Definitive Healthcare Announces Timing of Its Third Quarter 2025 Financial Results Conference Call and Webcast
FRAMINGHAM, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that ...
Forum Ventures Bets Big on Category-Defining Vertical AI Solution for Healthcare Growth, Salubrum
New York City, NY, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Salubrum, a vertical artificial intelligence (AI) company, has launched a category-defining commercialization engine for healthcare growth. In an i...
Definitive Healthcare Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Management has driven stabilization and transparency, aligning around four strategic pillars and leveraging domain expertise and data quality for differentiation. Life sciences face headwinds, but diversified and provider segments remain robust. Strong financials support investment in innovation, partnerships, and a long-term growth strategy.
Definitive Healthcare to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
FRAMINGHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that...
Definitive Healthcare Earnings Call Transcript: Q2 2025
Q2 2025 revenue and EBITDA exceeded guidance despite a 5% year-over-year revenue decline, with improved retention and strong professional services growth. Full-year guidance was raised, but macro pressures and Life Sciences downsell continue to weigh on outlook.
Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2025
FRAMINGHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, toda...
Definitive Healthcare Announces Timing of Its Second Quarter 2025 Financial Results Conference Call and Webcast
FRAMINGHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that ...
Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
FRAMINGHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of...
Definitive Healthcare Earnings Call Transcript: Q1 2025
Q1 revenue and adjusted EBITDA exceeded guidance despite a 7% year-over-year decline, with strong professional services growth and stabilized renewal rates. Full-year guidance was tightened, reflecting ongoing macro uncertainty and a focus on operational improvements.
Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025
FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today...
Definitive Healthcare Announces Timing of Its First Quarter 2025 Financial Results Conference Call and Webcast
FRAMINGHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that...
Definitive Healthcare Transcript: Raymond James & Associates’ 46th Annual Institutional Investors Conference 2025
The company is executing a turnaround focused on differentiated healthcare data, deeper integration, and improved customer retention. New data partnerships, operational restructuring, and cost initiatives are expected to drive margin and growth improvements, with full impact anticipated by late 2025 and into 2026.
Definitive Healthcare Earnings Call Transcript: Q4 2024
Q4 revenue and adjusted EBITDA exceeded guidance despite a 6% year-over-year revenue decline, with elevated churn—mainly downsells—impacting life sciences. 2025 guidance anticipates continued revenue pressure in H1, with improvement expected in H2 as new partnerships and operational changes take effect.
Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024
FRAMINGHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, toda...
Definitive Healthcare to Present at the Raymond James 2025 Institutional Investors Conference
FRAMINGHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that ...
Definitive Healthcare Announces Timing of Its Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast
FRAMINGHAM, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that ...